142I5 is a potent ML-IAP Lys-covalent inhibitor with an IC₅₀ value of 11 nM.

617.69

C₂₉H₃₆FN₅O₇S

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Udompholkul P, et al. Lysine Covalent Antagonists of Melanoma Inhibitors of Apoptosis Protein. J Med Chem. 2021 Nov 11;64(21):16147-16158.

142I5 is a potent ML-IAP Lys-covalent inhibitor with an IC₅₀ value of 11 nM.

617.69

C₂₉H₃₆FN₅O₇S

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Udompholkul P, et al. Lysine Covalent Antagonists of Melanoma Inhibitors of Apoptosis Protein. J Med Chem. 2021 Nov 11;64(21):16147-16158.

142I5 is a potent ML-IAP Lys-covalent inhibitor with an IC₅₀ value of 11 nM.

617.69

C₂₉H₃₆FN₅O₇S

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Udompholkul P, et al. Lysine Covalent Antagonists of Melanoma Inhibitors of Apoptosis Protein. J Med Chem. 2021 Nov 11;64(21):16147-16158.

B I09 is an IRE-1 RNase inhibitor, with an IC₅₀ of 1230 nM.

IC50: 1230 nM (IRE-1 RNase)^[1].

B I09 is an IRE-1 RNase inhibitor, with an IC₅₀ of 1230 nM^[1]. Treatment of CLL cells with this inhibitor (B I09) mimick XBP-1 deficiency, including upregulation of IRE-1 expression and compromised BCR signaling. B I09 is highly effective in inhibiting splicing of XBP1 mRNA in human WaC3 cells and the expression of XBP-1s in LPS stimulated B cells^[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

B I09 has a halflife of approximately 1.5 hours and reaches its peak concentration of approximately 39 μM in mouse plasma serum 15 minutes after administration. Administration of B I09 to CLL tumor-bearing mice suppress leukemic progression by inducing apoptosis and do not cause systemic toxicity^[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

303.31

C₁₆H₁₇NO₅

1607803-67-7

Room temperature in continental US; may vary elsewhere.

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

DMSO : 8.33 mg/mL (27.46 mM; Need ultrasonic)

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

• 1.

  请依序添加每种溶剂： 10% DMSO    90% (20% SBE-β-CD in saline)

  Solubility: 2.5 mg/mL (8.24 mM); Suspended solution; Need ultrasonic

  此方案可获得 2.5 mg/mL (8.24 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。

  以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

  将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明

• [1]. Ranatunga S, et al. Synthesis of novel tricyclic chromenone-based inhibitors of IRE-1 RNase activity. J Med Chem. 2014 May 22;57(10):4289-301.

  [2]. Tang CH, et al. Inhibition of ER stress-associated IRE-1/XBP-1 pathway reduces leukemic cell survival. J Clin Invest. 2014 Jun;124(6):2585-98.

Mice^[2]
Mice are intraperitoneally injected with B I09 (50 mg/kg) on the first 5 days of each week for 3 weeks^[2].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

• [1]. Ranatunga S, et al. Synthesis of novel tricyclic chromenone-based inhibitors of IRE-1 RNase activity. J Med Chem. 2014 May 22;57(10):4289-301.

  [2]. Tang CH, et al. Inhibition of ER stress-associated IRE-1/XBP-1 pathway reduces leukemic cell survival. J Clin Invest. 2014 Jun;124(6):2585-98.